BR112015023523B8 - Composições farmacêuticas e recipiente de forma de dosagem única - Google Patents

Composições farmacêuticas e recipiente de forma de dosagem única

Info

Publication number
BR112015023523B8
BR112015023523B8 BR112015023523A BR112015023523A BR112015023523B8 BR 112015023523 B8 BR112015023523 B8 BR 112015023523B8 BR 112015023523 A BR112015023523 A BR 112015023523A BR 112015023523 A BR112015023523 A BR 112015023523A BR 112015023523 B8 BR112015023523 B8 BR 112015023523B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
dosage form
single dosage
form container
compositions
Prior art date
Application number
BR112015023523A
Other languages
English (en)
Other versions
BR112015023523B1 (pt
BR112015023523A2 (pt
Inventor
Terracciano Joseph
Miller Damour Nicole
Jiang Chun
Fogliato Giovanni
Alessandro Donadelli Giuseppe
Resemini Dario
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50280243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015023523(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112015023523A2 publication Critical patent/BR112015023523A2/pt
Publication of BR112015023523B1 publication Critical patent/BR112015023523B1/pt
Publication of BR112015023523B8 publication Critical patent/BR112015023523B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

COMPOSIÇÕES DOS ANTIBIÓTICOS DE CEFTOLOZANE. A presente invenção refere-se a composições farmacêuticas compreendendo ceftolozane, com-posições farmacêuticas que compreende ceftolozane e tazobactama, métodos de preparação dessas composições e relacionadas aos métodos e usos dessas composições.
BR112015023523A 2013-03-15 2014-03-14 Composições farmacêuticas e recipiente de forma de dosagem única BR112015023523B8 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361792092P 2013-03-15 2013-03-15
US201361793007P 2013-03-15 2013-03-15
US61/792,092 2013-03-15
US61/793,007 2013-03-15
US201361882936P 2013-09-26 2013-09-26
US61/882,936 2013-09-26
US201361893436P 2013-10-21 2013-10-21
US61/893,436 2013-10-21
PCT/US2014/028642 WO2014144295A1 (en) 2013-03-15 2014-03-14 Ceftolozane antibiotic compositions

Publications (3)

Publication Number Publication Date
BR112015023523A2 BR112015023523A2 (pt) 2020-03-10
BR112015023523B1 BR112015023523B1 (pt) 2021-09-14
BR112015023523B8 true BR112015023523B8 (pt) 2023-03-07

Family

ID=50280243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023523A BR112015023523B8 (pt) 2013-03-15 2014-03-14 Composições farmacêuticas e recipiente de forma de dosagem única

Country Status (17)

Country Link
US (7) US20140274994A1 (pt)
EP (3) EP2893929A1 (pt)
JP (3) JP6543611B2 (pt)
KR (2) KR102226197B1 (pt)
CN (2) CN105392485B (pt)
AU (1) AU2014227660B2 (pt)
BR (1) BR112015023523B8 (pt)
CA (1) CA2906151A1 (pt)
CL (1) CL2015002755A1 (pt)
EA (1) EA029090B1 (pt)
IL (1) IL241581B (pt)
MX (2) MX2020004205A (pt)
NZ (1) NZ700372A (pt)
PE (1) PE20160048A1 (pt)
TN (1) TN2015000411A1 (pt)
UA (1) UA121298C2 (pt)
WO (1) WO2014144295A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801521B (zh) 2007-05-14 2015-06-17 纽约州立大学研究基金会 生物膜中细菌细胞内的生理学分散响应诱导
EA028342B1 (ru) 2011-09-09 2017-11-30 Мерк Шарп И Доум Корп. Способы лечения пневмонии
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140275000A1 (en) * 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
WO2014144295A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane antibiotic compositions
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) * 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN104721190B (zh) * 2015-03-26 2017-01-11 新乡医学院 头孢替唑钠注射液及其制备方法
MX2017013434A (es) * 2016-03-31 2018-01-30 Wockhardt Ltd Composiciones antibacterianas.
CA2983256A1 (en) * 2016-03-31 2017-10-05 Wockhardt Limited Antibacterial compositions
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2023039947A1 (zh) * 2021-09-18 2023-03-23 湘北威尔曼制药股份有限公司 一种含有头孢哌酮钠和他唑巴坦钠的药物组合物及其应用
WO2023149411A1 (ja) * 2022-02-01 2023-08-10 いなば食品株式会社 動物用の医薬又は食品組成物

Family Cites Families (252)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL37879A (en) 1970-10-27 1974-12-31 Ciba Geigy Ag 3-unsubstituted cephalosporin derivatives,process for their manufacture and compositions containing them
US4299829A (en) 1976-03-12 1981-11-10 Fujisawa Pharmaceutical Co., Ltd. 2-Lower alkyl-7-substituted-2 or 3-cephem 4-carboxylic acid compounds
US4409217A (en) 1977-03-14 1983-10-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4496562A (en) 1977-03-14 1985-01-29 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted-3-cephem-4-carboxylic acid esters
PH17188A (en) 1977-03-14 1984-06-14 Fujisawa Pharmaceutical Co New cephem and cepham compounds and their pharmaceutical compositions and method of use
US4464369A (en) 1977-03-14 1984-08-07 Fujisawa Pharmaceutical Co., Ltd. 7-Acylamino-3-cephem-4-carboxylic acid derivatives and pharmaceutical compositions
JPS543087A (en) 1977-06-03 1979-01-11 Fujisawa Pharmaceut Co Ltd Preparation of cephalosporin compound
GB1604738A (en) 1977-07-28 1981-12-16 Yamanouchi Pharma Co Ltd 1,3-dithietane-2-carboxylic acid derivatives and the preparation thereof
JPS609719B2 (ja) 1977-08-06 1985-03-12 武田薬品工業株式会社 セフアロスポリン誘導体およびその製造法
US4370326A (en) 1977-09-13 1983-01-25 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and composition
IT1192287B (it) 1977-11-14 1988-03-31 Fujisawa Pharmaceutical Co Derivati di acido cefalosporanico ad azione farmaceutica e relativo procedimento di preparazione
US4363807A (en) 1978-04-06 1982-12-14 Fujisawa Pharmaceutical Company, Limited Cepham compounds
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
AR229883A1 (es) 1978-05-26 1983-12-30 Glaxo Group Ltd Procedimiento para la preparacion de antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)-acetamido)-3-(1-piridinometil)-cef-3-em-4-carboxilato
US4264597A (en) 1978-06-06 1981-04-28 Masashi Hashimoto Cephalosporin analogues and processes for the preparation thereof
US4268509A (en) 1978-07-10 1981-05-19 Fujisawa Pharmaceutical Co., Ltd. New cephem compounds and processes for preparation thereof
US4284631A (en) 1978-07-31 1981-08-18 Fujisawa Pharmaceutical Co., Ltd. 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them
US4305937A (en) 1978-08-17 1981-12-15 Fujisawa Pharmaceutical Co., Ltd. 2-Lower alkyl-7-substituted-2 or 3-cephem-4-carboxylic acid compounds and antibacterial pharmaceutical compositions containing them
US4703046A (en) 1978-09-08 1987-10-27 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and processes for preparation thereof
EP0048504B1 (en) 1978-09-12 1988-08-17 Fujisawa Pharmaceutical Co., Ltd. Intermediate compounds for preparing cephem compounds; processes for their preparation and processes for preparing cephem compounds
US4327093A (en) 1978-10-24 1982-04-27 Fujisawa Pharmaceutical Co., Ltd. 3,7-Disubstituted-2 or 3-cephem-4-carboxylic acid compounds
DE2945248A1 (de) 1978-11-13 1980-05-22 Fujisawa Pharmaceutical Co Cephem-verbindungen, verfahren zu ihrer herstellung und sie enthaltende antibakterielle pharmazeutische mittel
US4332798A (en) 1978-12-29 1982-06-01 Fujisawa Pharmaceutical Co., Ltd. 7-Amino-thia-diazole oxyimino derivatives of cephem and cephem compounds
US4390534A (en) 1978-12-29 1983-06-28 Fujisawa Pharmaceutical Co., Ltd. Cephem and cepham compounds
AU536842B2 (en) 1978-12-29 1984-05-24 Fujisawa Pharmaceutical Co., Ltd. Cephalosporin antibiotics
US4291031A (en) 1979-02-19 1981-09-22 Fujisawa Pharmaceutical Co., Ltd. 3-Phosphonocephalosporanic acid derivatives, and pharmaceutical composition comprising the same
US4339449A (en) 1979-03-27 1982-07-13 Fujisawa Pharmaceutical Company, Limited Analogous compounds of cephalosporins, and pharmaceutical composition comprising the same
FR2462439A1 (fr) 1979-07-26 1981-02-13 Roussel Uclaf Nouveau procede de preparation de produits derives de l'acide 7-/(2-aryl) 2-hydroxyimino acetamido/cephalosporanique
EP0025199B1 (en) 1979-09-03 1984-10-31 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds, processes for their preparation and pharmaceutical compositions containing them
US4381299A (en) 1980-03-07 1983-04-26 Fujisawa Pharmaceutical Co., Ltd. 7-Amino-thiadiazole oxyimino derivatives of cephem and cepham compounds
US4338313A (en) 1979-10-12 1982-07-06 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4332800A (en) 1979-10-12 1982-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4409215A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical Co., Ltd. 7-Acylamino-3-substituted cephalosporanic acid derivatives and processes for the preparation thereof
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4420477A (en) 1979-11-30 1983-12-13 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4443443A (en) 1979-12-17 1984-04-17 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4405617A (en) 1980-02-11 1983-09-20 Fujisawa Pharmaceutical Co., Ltd. 3-(Propynyltetrazol)thiomethyl-3-cephems
JPS56125392A (en) 1980-03-06 1981-10-01 Fujisawa Pharmaceut Co Ltd Cepham and cephem compound and preparation thereof
US4470980A (en) 1980-03-07 1984-09-11 Interx Research Corp. Method of increasing oral absorption of β-lactam antibiotics
JPS5711909A (en) 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
DE3173613D1 (en) 1980-07-04 1986-03-13 Fujisawa Pharmaceutical Co 7-oxo-cephalosporins and 6-oxo-penicillins, their analogues and process for their preparation
US4443444A (en) 1980-08-11 1984-04-17 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE3175156D1 (en) 1980-08-29 1986-09-25 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US4416879A (en) 1980-09-08 1983-11-22 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GR78245B (pt) 1980-09-12 1984-09-26 Ciba Geigy Ag
US4367228A (en) 1980-10-29 1983-01-04 Fujisawa Pharmaceutical Co., Ltd. Cephem compound and composition
US4431642A (en) 1980-12-01 1984-02-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
ES8303422A1 (es) 1980-12-15 1983-02-01 Fujisawa Pharmaceutical Co Un procedimiento para preparar derivados del acido 7-acilaminocefalosporanico .
US4427677A (en) 1980-12-31 1984-01-24 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
EP0055465B1 (en) 1980-12-31 1989-08-23 Fujisawa Pharmaceutical Co., Ltd. 7-acylaminocephalosporanic acid derivatives and processes for the preparation thereof
GR76342B (pt) 1981-02-02 1984-08-06 Fujisawa Pharmaceutical Co
US4336253A (en) 1981-03-11 1982-06-22 Eli Lilly And Company Cephalosporin antibiotics
JPS6011917B2 (ja) 1981-04-09 1985-03-28 山之内製薬株式会社 新規なセファロスポリン化合物
DE3118732A1 (de) 1981-05-12 1982-12-02 Hoechst Ag, 6000 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
JPS57193489A (en) 1981-05-21 1982-11-27 Fujisawa Pharmaceut Co Ltd Syn-isomer of 7-substituted-3-cephem-4-carboxylic acid ester and its preparation
GR75487B (pt) 1981-06-22 1984-07-23 Fujisawa Pharmaceutical Co
IE53429B1 (en) 1981-08-03 1988-11-09 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US4430499A (en) 1981-09-08 1984-02-07 Eli Lilly And Company 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido]cephalosporin antibiotics
US4436912A (en) 1981-09-08 1984-03-13 Eli Lilly And Company 7-[2-(2-Aminooxazol-4-yl)-2-(oximino)acetamido cephalosporin antibiotics and intermediates therefor
US4577014A (en) 1981-09-08 1986-03-18 Eli Lilly And Company Thieno and furopyridinium-substituted cephalosporins
US4521413A (en) 1981-09-14 1985-06-04 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
JPS5859991A (ja) 1981-09-14 1983-04-09 Fujisawa Pharmaceut Co Ltd 新規セフェム化合物
US4402955A (en) 1981-10-02 1983-09-06 Eli Lilly And Company Dioximino cephalosporin antibiotics
US4450270A (en) 1981-10-02 1984-05-22 Eli Lilly And Company Dioximino cephalosporin antibiotics
US4501739A (en) 1982-01-19 1985-02-26 Eli Lilly And Company Thieno and furopyridinium-substituted cephalosporins
DE3207840A1 (de) 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
JPS58154547A (ja) 1982-03-09 1983-09-14 Nippon Shinyaku Co Ltd アズレン誘導体の安定化法
US4640915A (en) 1982-03-29 1987-02-03 Fujisawa Pharmaceutical Co., Ltd. 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid derivatives
JPS58225091A (ja) 1982-06-21 1983-12-27 Taiho Yakuhin Kogyo Kk ペニシリン誘導体及びその製造法
AU541028B2 (en) 1982-06-21 1984-12-13 Taiho Pharmaceutical Co., Ltd. 6-unsubstituted penicillin derivatives
US4563449A (en) 1982-07-19 1986-01-07 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4546101A (en) 1982-09-10 1985-10-08 Fujisawa Pharmaceutical Co., Ltd. New cephem compounds useful for treating infectious diseases in human being and animals and processes for preparation thereof
GB8323034D0 (en) 1983-08-26 1983-09-28 Fujisawo Pharmaceutical Co Ltd 7-substituted-3-vinyl-3-cephem compounds
US4609730A (en) 1982-11-22 1986-09-02 Fujisawa Pharmaceutical Co., Ltd. 7-[substituted imino-2-(2-aminothiazol-4-yl)-acetamido]-3(2,2-dihalovinyl or ethynyl)-3-cephem-4-carboxylic acid (syn isomers), having antimicrobial activities
GR79043B (pt) 1982-12-06 1984-10-02 Fujisawa Pharmaceutical Co
US4608373A (en) 1982-12-13 1986-08-26 Yamanouchi Pharmaceutical Co., Ltd. Cephem compounds
US4463003A (en) 1982-12-22 1984-07-31 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4487768A (en) 1982-12-22 1984-12-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE3247613A1 (de) 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
US4562073A (en) 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US4499088A (en) 1983-01-04 1985-02-12 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
DE3316798A1 (de) 1983-05-07 1984-11-08 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von cephemverbindungen
FR2550200B1 (fr) 1983-08-01 1988-04-08 Fujisawa Pharmaceutical Co Procede de preparation de composes de cephem a activite antimicrobienne et nouveaux produits ainsi obtenus
JPS6045514A (ja) 1983-08-22 1985-03-12 Shionogi & Co Ltd 安定な抗菌性凍結乾燥製剤
EP0137442A3 (de) 1983-10-08 1986-01-15 Hoechst Aktiengesellschaft Cephalosporinderivate und Verfahren zu ihrer Herstellung
DE3409431A1 (de) 1983-10-08 1985-04-18 Hoechst Ag, 6230 Frankfurt Cephalosporinderivate und verfahren zu ihrer herstellung
US4690921A (en) 1983-10-11 1987-09-01 Yamanouchi Pharmaceutical Co., Ltd. Cephalosporin compounds and salts thereof
US4748172A (en) 1983-10-17 1988-05-31 Eli Lilly And Company 3-bicyclicpyridinium-methyl cephalosporins
US4692443A (en) 1983-10-17 1987-09-08 Eli Lilly And Company 3-bicyclicpyridinium-methyl cephalosporins
ZA847926B (en) 1983-10-17 1986-05-28 Lilly Co Eli 3-bicyclicpyridinium-methyl cephalosporins
GB8329030D0 (en) 1983-10-31 1983-11-30 Fujisawa Pharmaceutical Co Cephem compounds
GB8401093D0 (en) 1984-01-16 1984-02-15 Fujisawa Pharmaceutical Co Cephem compounds
JPS60169486A (ja) 1984-02-10 1985-09-02 Yamanouchi Pharmaceut Co Ltd ７−アミノ−３−置換メチル−３−セフエム−４−カルボン酸およびその低級アルキルシリル誘導体の製造法
GB8406231D0 (en) 1984-03-09 1984-04-11 Fujisawa Pharmaceutical Co Cephem compounds
JPS60214792A (ja) 1984-04-06 1985-10-28 Taiho Yakuhin Kogyo Kk ペナム酸エステル誘導体
US4705851A (en) 1984-09-28 1987-11-10 Fujisawa Pharmaceutical Co., Ltd. Process for the preparation of 3-phosphoniummethyl-3-cephem compounds
US4761410A (en) 1985-01-14 1988-08-02 Fujisawa Pharmaceutical Co., Ltd. Cephem Compounds
US4808711A (en) 1985-01-21 1989-02-28 Sankei Pharmaceutical Co., Ltd. Cephalosporin derivatives
GB8504072D0 (en) 1985-02-18 1985-03-20 Fujisawa Pharmaceutical Co Cephem compounds
JPS62103092A (ja) 1985-07-18 1987-05-13 Sagami Chem Res Center β−ラクタム誘導体
JPS6230789A (ja) 1985-08-01 1987-02-09 Yamanouchi Pharmaceut Co Ltd ７−ホルミルアミノセフアロスポリン化合物およびその製造法
CN86107947A (zh) 1985-11-22 1987-05-27 藤沢药品工业株式会社 新的头孢烯化合物及其制备方法
US5194432A (en) 1985-11-22 1993-03-16 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4808617A (en) 1985-12-18 1989-02-28 Bristol-Myers Company Lyophilized or precipitated cephalosporin zwitterion and salt combination
JPS62158290A (ja) 1985-12-28 1987-07-14 Banyu Pharmaceut Co Ltd 新規セフアロスポリン誘導体
DE3789466T2 (de) 1986-03-17 1994-07-28 Fujisawa Pharmaceutical Co 3,7-Disubstituierte-3-Cephemverbindungen und Verfahren zu ihrer Herstellung.
JP2690009B2 (ja) * 1986-07-10 1997-12-10 エーザイ 株式会社 セフアロスポリン注射剤
US4833134A (en) 1986-08-19 1989-05-23 Takeda Chemical Industries, Ltd. Cephem compounds
JPS6351389A (ja) 1986-08-22 1988-03-04 Teijin Ltd セフアロスポリン誘導体、その製造法及び抗菌活性組成物
JPS6351388A (ja) 1986-08-22 1988-03-04 Teijin Ltd セフアロスポリン誘導体、その製造法及び抗菌活性組成物
CA1293719C (en) 1986-09-22 1991-12-31 Takao Takaya Cephem compounds and processes for preparation thereof
US5162520A (en) 1986-09-22 1992-11-10 Fujisawa Pharmaceutical Co., Ltd. Intermediates for cephem compounds
US4882434A (en) 1986-10-29 1989-11-21 Takeda Chemical Industries, Ltd. Gamma-lactonecarboxylic acid derivatives and their use as antibacterial agents or intermediates
DE3784147T2 (de) 1986-11-24 1993-06-03 Fujisawa Pharmaceutical Co 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-en-2-carbonsaeure-derivate.
KR880006244A (ko) 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법
AU1630988A (en) 1987-05-30 1988-12-01 Kyoto Pharmaceutical Industries, Ltd. Cephalosporin compound and pharmaceutical composition thereof
IE61679B1 (en) 1987-08-10 1994-11-16 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
US5073550A (en) 1987-08-14 1991-12-17 Hoffmann-La Roche Inc. Cephalosphorins with sulfur-containing oxyimino side chain
US5138066A (en) 1987-08-14 1992-08-11 Hoffmann-La Roche, Inc. Intermediates for cephalosporins with sulfur-containing oxyimino side chain
EP0303172A3 (de) 1987-08-14 1991-05-15 F. Hoffmann-La Roche Ag Oxyimino-Cephalosporine
ZA885709B (en) 1987-08-19 1989-04-26 Fujisawa Pharmaceutical Co Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid(syn isomer)
US5663163A (en) 1987-09-07 1997-09-02 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds and processes for preparation thereof
US5210080A (en) 1987-09-07 1993-05-11 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
IE63094B1 (en) 1987-09-14 1995-03-22 Fujisawa Pharmaceutical Co Cephem compound and a process for preparation thereof
DK637888A (da) 1987-11-24 1989-05-25 Hoffmann La Roche Carboxylsyreestere
GB8804058D0 (en) 1988-02-22 1988-03-23 Fujisawa Pharmaceutical Co 3-alkenyl-1-azabicyclo(3 2 0)hept-2-ene-2-carboxylic acid compounds
JP2648750B2 (ja) 1988-03-02 1997-09-03 大塚化学株式会社 β−ラクタム誘導体の製造方法
US5173485A (en) 1988-03-09 1992-12-22 Fujisawa Pharmaceutical Company, Ltd. Cephem compounds
US5336768A (en) 1988-05-24 1994-08-09 Hoffmann-La Roche Inc. Antibacterial cephalosporin compounds
CS273349B2 (en) 1988-03-31 1991-03-12 Hoffmann La Roche Method of cephalosporin's new derivatives production
KR900006811B1 (ko) 1988-05-11 1990-09-21 주식회사 럭 키 신규 세팔로스포린 유도체 및 그의 제조방법
US4963544A (en) 1988-05-23 1990-10-16 Fujisawa Pharmaceutical Company, Ltd. 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds
US5244890A (en) 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
EP0997466A1 (en) 1988-10-24 2000-05-03 PROCTER & GAMBLE PHARMACEUTICALS, INC. Novel antimicrobial lactam-quinolones
JP2785195B2 (ja) 1989-01-11 1998-08-13 ソニー株式会社 ディスク装置の光学式エンコーダ
GB8905301D0 (en) 1989-03-08 1989-04-19 Fujisawa Pharmaceutical Co New cephem compound and a process for preparation thereof
JPH0347187A (ja) 1989-04-12 1991-02-28 Yamanouchi Pharmaceut Co Ltd 新規なセファロスポリン誘導体
US5102877A (en) 1989-04-28 1992-04-07 Fujisawa Pharmaceutical Co., Ltd. 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds
NO903360L (no) 1989-08-11 1991-02-12 Ici Pharma Antibiotiske forbindelser.
ATE97810T1 (de) * 1989-09-30 1993-12-15 Eisai Co Ltd Injizierbare cephalosporinpraeparate und ihre anwendung.
GB8923844D0 (en) 1989-10-23 1989-12-13 Fujisawa Pharmaceutical Co Carbapenem compounds
US5215982A (en) 1989-11-10 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
US4982596A (en) 1990-01-26 1991-01-08 Buell Industries, Inc. Die for manufacturing a fastener blank
KR910015587A (ko) 1990-02-27 1991-09-30 후지사와 토모키치로 세펨 화합물
US5095012A (en) 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5234920A (en) 1990-08-23 1993-08-10 Bristol-Myers Squibb Company Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5286721A (en) 1990-10-15 1994-02-15 Fujisawa Pharmaceutical Co., Ltd. 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds
US5281589A (en) 1991-06-15 1994-01-25 Cheil Foods & Chemicals, Inc. 3-fused pyridiniummethyl cephalosporins
US5523400A (en) 1993-04-16 1996-06-04 Hoffmann-La Roche Inc. Cephalosporin antibiotics
KR100194994B1 (ko) 1993-06-05 1999-06-15 손경식 새로운 세펨 화합물
EP0678095A1 (en) 1993-11-06 1995-10-25 Taiho Pharmaceutical Co., Ltd. Crystalline penicillin derivative, and its production and use
EP0664117A1 (de) 1994-01-25 1995-07-26 F. Hoffmann-La Roche Ag Liposomenlösungen
TW293010B (en) 1994-04-20 1996-12-11 Hui-Po Wang Method for preparing cephalosporin derivatives
EP0723966A4 (en) 1994-08-16 1997-01-29 Meiji Seika Co NEW DERIVATIVES FROM CEPHEM
DE4440141A1 (de) 1994-11-10 1996-05-15 Hoechst Ag Neue kristalline Cephem-Säureadditionssalze und Verfahren zu ihrer Herstellung
JPH09110877A (ja) 1995-10-17 1997-04-28 Katayama Seiyakushiyo:Kk セフェム化合物、その製造法及びそれを含有する抗菌剤
EP1671966A1 (en) 1996-04-04 2006-06-21 Shionogi & Co., Ltd. Cephem compounds and pharmaceutical compositions containing the same
AUPN955596A0 (en) 1996-04-30 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1999028308A1 (en) 1997-11-29 1999-06-10 Truett William L Antibiotics and process for preparation
CA2319495A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
WO2000004915A1 (en) 1998-07-23 2000-02-03 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the treatment or prevention of pulmonary infections
TW526202B (en) 1998-11-27 2003-04-01 Shionogi & Amp Co Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
US6207661B1 (en) 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection
TWI233805B (en) 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
WO2001012171A2 (en) 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases
ES2305065T3 (es) 2000-04-24 2008-11-01 Daiichi Sankyo Company, Limited Preparacion liquida estable que contiene sitafloxacina.
JP3743823B2 (ja) 2000-08-11 2006-02-08 大塚化学ホールディングス株式会社 ペニシリン結晶及びその製造法
JP3743822B2 (ja) 2000-08-11 2006-02-08 大塚化学ホールディングス株式会社 ペニシリン結晶及びその製造法
US6599893B2 (en) 2000-08-29 2003-07-29 Essential Therapeutics, Inc. Cephalosporin antibiotics and prodrugs thereof
JP3306473B1 (ja) 2001-05-01 2002-07-24 大塚化学株式会社 β−ラクタム化合物の無水結晶及びその製造法
NZ529887A (en) 2001-05-01 2005-05-27 Fujisawa Pharmaceutical Co Cephem compounds
JP2002338578A (ja) 2001-05-14 2002-11-27 Otsuka Chem Co Ltd β−ラクタム化合物の水和物結晶
US7166626B2 (en) 2001-06-18 2007-01-23 Revaax Pharmaceuticals, Llc Therapeutic treatment for sexual dysfunction
TWI335332B (en) 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
AU2003210925A1 (en) 2002-02-07 2003-09-02 Rutgers, The State University Antibiotic polymers
TW200305422A (en) 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
US6878686B2 (en) 2002-05-24 2005-04-12 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
CN1285596C (zh) 2002-06-07 2006-11-22 奥齐德化学和制药有限公司 由头孢烷衍生物制备青霉烷衍生物的方法
WO2004019901A2 (en) 2002-08-30 2004-03-11 Orchid Chemicals & Pharmaceuticals Ltd. Sustained release pharmaceutical composition
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
AU2002952355A0 (en) * 2002-10-30 2002-11-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
ES2290498T7 (es) * 2002-10-30 2015-07-10 Astellas Pharma Inc. Compuestos de cefem
AU2003274518A1 (en) 2002-11-01 2004-05-25 Orchid Chemicals And Pharmaceuticals Ltd A process for the preparation of benzyl 2-oxo-4- (heteroaryl) dithio-alpha-isoprenyl-1- azetidineazetate derivatives
EP1897959A1 (en) 2002-11-22 2008-03-12 The Johns Hopkins University Target for therapy of cognitive impairment
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
JP2004269401A (ja) * 2003-03-07 2004-09-30 Sawai Pharmaceutical Co Ltd 凍結乾燥製剤
CN1802179B (zh) 2003-04-14 2011-09-14 惠氏控股公司 含有哌拉西林和三唑巴坦的注射用组合物
WO2004098643A1 (en) 2003-04-14 2004-11-18 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
AU2003902380A0 (en) 2003-05-16 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
WO2004113350A1 (en) 2003-05-23 2004-12-29 Theravance, Inc. Cross-linked glycopeptide - cephalosporin antibiotics
DE602004012269T2 (de) 2003-07-11 2009-04-30 Theravance, Inc., South San Francisco Quervernetzte glycopeptid-cephalosporin-antibiotika
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7273935B2 (en) 2003-08-21 2007-09-25 Orchid Chemicals & Pharmaceuticals, Ltd. Process for the preparation of 3-methylcepham derivatives
EP1663245B1 (en) 2003-09-18 2010-04-07 Astellas Pharma Inc. Cephem compounds
FR2860235A1 (fr) 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
TW200523264A (en) 2003-10-09 2005-07-16 Otsuka Chemical Co Ltd CMPB crystal and method for producing the same
TW200519119A (en) 2003-10-10 2005-06-16 Otsuka Chemical Co Ltd PENAM crystal and process for producing the same
JP4535366B2 (ja) 2003-12-03 2010-09-01 塩野義製薬株式会社 セフェム剤の製造方法
KR20060127931A (ko) 2004-01-30 2006-12-13 와이어쓰 피페라실린 및 타조박탐을 포함하고 실질적으로갈락토만난을 포함하지 않는 조성물
AU2005219718A1 (en) 2004-03-05 2005-09-15 Shionogi & Co., Ltd. 3-pyridinium methylcephem compound
US7417143B2 (en) 2004-04-07 2008-08-26 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of Tazobactam in pure form
RU2007111484A (ru) 2004-10-14 2008-11-20 Вайет (Us) Составы, содержащие пиперациллин, тазобактам и аминокарбоновую кислоту в растворителе лактата натрия
US20060099253A1 (en) 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
US20060173177A1 (en) 2005-01-28 2006-08-03 Gego Csaba L Process for preparation of penam derivatives
CA2597812C (en) * 2005-02-14 2012-01-24 Venus Remedies Limited Parenteral combination therapy for infective conditions with drug resistant bacterium
WO2006088305A1 (en) 2005-02-15 2006-08-24 Chong Kun Dang Pharmaceutical Corp. Gastric-retentive controlled release mono-matrix tablet
CA2611577A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
ITMI20051630A1 (it) 2005-09-02 2007-03-03 Acs Dobfar Spa Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
US20070116649A1 (en) * 2005-09-29 2007-05-24 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
EP1787641A1 (de) 2005-11-22 2007-05-23 Helm AG Tazobactam-Piperacillin-Lyophilisat
DE602006017732D1 (de) 2005-12-05 2010-12-02 Sandoz Ag Verfahren zur herstellung von lyophilisiertem piperacillin-natrium in kombination mit tazobactam-natrium, mit verbesserter stabilität nach der rekonstitution
WO2007086014A1 (en) 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefpirome, tazobactam and linezolid
WO2007086013A1 (en) 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising of ceftazidime, tazobactam and linezolid
WO2007086011A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefepime, tazobactam and linezolid
WO2008075207A2 (en) 2006-04-04 2008-06-26 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
WO2007129176A2 (en) 2006-04-28 2007-11-15 Wockhardt Ltd Improvements in therapy for treating resistant bacterial infections
WO2007145868A1 (en) 2006-06-07 2007-12-21 Wyeth Treating cystic fibrosis with antibiotics via an aerosol drug
WO2007145866A1 (en) 2006-06-07 2007-12-21 Wyeth Treating cystic fibrosis with antibiotics via a swirler delivery
US20070286818A1 (en) 2006-06-07 2007-12-13 Wyeth Treating cystic fibrosis with antibiotics via an aerosol drug
US20070286817A1 (en) 2006-06-07 2007-12-13 Wyeth Treating cystic fibrosis with antibiotics via a swirler delivery
PL2046802T3 (pl) 2006-07-12 2014-01-31 Allecra Therapeutics Gmbh 2-podstawione pochodne metylopenemu
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN101129381B (zh) 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
US20080160067A1 (en) 2006-09-07 2008-07-03 Albert Boeckh Novel soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations
US20080103121A1 (en) * 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
FI119678B (fi) 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
ES2633020T3 (es) 2006-12-10 2017-09-18 Yu, Chongxi-Techfields Biochem Sistemas de administración transdérmica de antibióticos betalactámicos
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
ES2704439T3 (es) 2007-03-20 2019-03-18 Scf Pharma Inc Composiciones que comprenden monoglicéridos de ácidos grasos poliinsaturados o derivados de los mismos y usos de los mismos
ITMI20070568A1 (it) 2007-03-22 2008-09-23 Acs Dobfar Spa Comosizione farmaceutica sterile iniettabile avente piperacillina sodica e tazobactam sodico come principi attivi
US20090098088A1 (en) 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
EP2285216A4 (en) 2008-02-21 2012-09-19 Sequoia Pharmaceuticals Inc HIV PROTEASE INHIBITOR AND COMBINED CYTOCHROME P450 INHIBITOR
TW200940552A (en) * 2008-03-04 2009-10-01 Elan Pharm Inc Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens
ITPI20080025A1 (it) 2008-03-31 2009-10-01 Italmed S R L Composizione ad uso odontoiatrico per il trattamento delle perimplantiti
CA2721981A1 (en) 2008-05-01 2009-11-05 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
CN101265263B (zh) * 2008-05-12 2010-06-02 海南百那医药发展有限公司 哌拉西林钠他唑巴坦钠复方注射剂的生产方法
WO2009138847A2 (en) * 2008-05-14 2009-11-19 Orchid Chemicals And Pharmaceuticals Ltd. An improved process for the preparation of cefozopran
WO2010014285A1 (en) 2008-07-30 2010-02-04 Estabrook Pharmaceuticals, Inc. Compositions including clavulanic acid and related methods of use
RU2586287C2 (ru) 2009-06-10 2016-06-10 Текфилдз Байокем Ко., Лтд. Композиции или пролекарства противомикробных и родственных противомикробным соединений, обладающие высокой проникающей способностью
EP2458995A1 (en) 2009-07-28 2012-06-06 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
EP2536408A1 (en) 2010-02-16 2012-12-26 Wockhardt Research Centre Efflux pump inhibitors
EP2544528A1 (en) 2010-03-09 2013-01-16 Merck Sharp & Dohme Corp. FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS
JP2013523830A (ja) 2010-04-06 2013-06-17 プリサイエンス ラブス， エルエルシー ３−ブロモピルバートおよび他のａｔｐ産生の選択的阻害剤を用いる処置の方法
NZ617104A (en) * 2011-07-26 2015-05-29 Wockhardt Ltd Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
EA028342B1 (ru) * 2011-09-09 2017-11-30 Мерк Шарп И Доум Корп. Способы лечения пневмонии
EP2900244B1 (en) 2012-09-27 2019-10-23 Merck Sharp & Dohme Corp. Tazobactam arginine antibiotic compositions
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
WO2014144295A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane antibiotic compositions
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions

Also Published As

Publication number Publication date
EP2893929A1 (en) 2015-07-15
KR102226197B1 (ko) 2021-03-11
WO2014144295A8 (en) 2015-04-23
TN2015000411A1 (en) 2017-01-03
MX2015012833A (es) 2016-06-10
PE20160048A1 (es) 2016-02-12
JP2021102652A (ja) 2021-07-15
MX2020004205A (es) 2021-11-16
CN105392485A (zh) 2016-03-09
US20160279140A1 (en) 2016-09-29
AU2014227660B2 (en) 2014-11-06
US20140274989A1 (en) 2014-09-18
US20140274994A1 (en) 2014-09-18
WO2014144295A4 (en) 2014-11-13
JP7177314B2 (ja) 2022-11-24
KR102329764B1 (ko) 2021-11-23
US20140274992A1 (en) 2014-09-18
US9044485B2 (en) 2015-06-02
NZ711823A (en) 2021-05-28
NZ700372A (en) 2016-01-29
US20140309205A1 (en) 2014-10-16
JP6543611B2 (ja) 2019-07-10
JP2019151668A (ja) 2019-09-12
EP2777705A1 (en) 2014-09-17
EA201591712A1 (ru) 2016-04-29
AU2014227660A1 (en) 2014-10-09
UA121298C2 (uk) 2020-05-12
KR20150135363A (ko) 2015-12-02
CN105392485B (zh) 2019-08-02
AU2014227660A8 (en) 2014-10-23
EA029090B1 (ru) 2018-02-28
BR112015023523B1 (pt) 2021-09-14
JP6870029B2 (ja) 2021-05-12
CL2015002755A1 (es) 2016-12-23
JP2016517436A (ja) 2016-06-16
BR112015023523A2 (pt) 2020-03-10
CN110279698A (zh) 2019-09-27
US20140303136A1 (en) 2014-10-09
EP3100732A1 (en) 2016-12-07
US20140274995A1 (en) 2014-09-18
KR20210031758A (ko) 2021-03-22
IL241581B (en) 2020-11-30
CN110279698B (zh) 2022-10-28
CA2906151A1 (en) 2014-09-18
WO2014144295A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
BR112015023523B8 (pt) Composições farmacêuticas e recipiente de forma de dosagem única
IL285390A (en) Arylquinazolines, their preparation and pharmaceutical preparations containing them
FR21C1059I2 (fr) Compositions pharmaceutiques
IL243608A0 (en) Substances with antiviral activity, preparations containing them and their uses
HK1215191A1 (zh) 低劑量醫藥組合物
BR112016008736A2 (pt) formulação estável de insulina glulisina
IN2013MU03641A (pt)
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
IL246406A0 (en) History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
EP2999461A4 (en) Targeted delivery of drugs to the myometrium
AU2014271207A1 (en) Targeted delivery of drugs to the myometrium
HK1223833A1 (zh) 藥物劑型
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
UY34595A (es) Composición farmacéutica de liberación prolongada de trimetazidina
IL239873B (en) The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
EA201400444A1 (ru) Производные 2-оксопиперидинила
MX2016006742A (es) Composicion farmaceutica.
IN2013MU02528A (pt)
DK2953617T3 (da) Farmaceutiske sammensætninger, der inkorporerer lavdosislægemidler
MX366763B (es) Composiciones farmacéuticas de montelukast y levocetirizina.
AU2013901842A0 (en) Targeted delivery of drugs to the myometrium
IN2013MU02715A (pt)
DK3071267T3 (da) Lægemiddeladministrationsanordning med ensrettet kobling

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)